eli lilly tirzepatide fda approval OKs Zepbound for weight-loss New Medication approved by the

semaglutide, Truveta Data enabled researchers to assess how these medications perform head-to-head in a large, diverse population

Kombucha: A fermented tea drink that is rich in probiotics

Interpretation of findings Weight loss improves cardiovascular risk factorsa recent trial showed that continuous use of semaglutide over four years reduced major cardiovascular disease events in individuals with existing cardiovascular disease.9 The benefits of weight loss on diabetes and other cardiovascular disease risk markers were, however, attenuated by weight regain.10 Based on projections of observed trends, we estimated that people who stop taking WMMs will regain weight at a rate of 0.4 kg/month, returning to baseline weight by 1.7 years and to no difference from control after 1.4 years

One way to minimise diagnostic delays is to rectify the disbelief of doctors and the stigmatization around ME/CFS (53, 533, 534)